KVKatja Välimäki

Katja Välimäki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katja Välimäki has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Olli Kallioniemi

    Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences-HiLIFE, University of Helsinki, Finland

    4 shared publications
  • Teijo Pellinen

    Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences-HiLIFE, University of Helsinki, Finland

    4 shared publications
  • Tuomas Mirtti

    Research Program in Systems Oncology, Faculty of Medicine University of Helsinki Helsinki Finland

    3 shared publications
  • Antti Rannikko

    Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland

    2 shared publications
  • Caroline A. Heckman

    University of Helsinki

    2 shared publications
  • Harri Mustonen

    Abdominal Center, Department of Gastrointestinal Surgery, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland

    2 shared publications

Latest Publications

  • Open Access

    Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities

    by Frida Rantanen, Astrid Murumägi, Mariliina Arjama, Katja Välimäki, Elina Multamäki, Tuomas Mirtti, Antti Rannikko, Teijo Pellinen, Daniela Ungureanu, Olli Kallioniemi

    Cancer-associated fibroblasts (CAFs) are central architects of the prostate cancer (PCa) microenvironment, yet their phenotypic diversity and druggable vulnerabilities remain largely uncharted. Here, we present an integrative multi-omics characterization of primary ex vivo CAFs from seven treatment-naïve PCa patients. Using single-cell RNA sequencing (scRNA-seq), we uncover substantial transcriptional heterogeneity among CAFs, with distinct gene expression programs related to extracellular matrix remodeling, inflammation, immune modulation, and metabolic reprogramming. This phenotypic diversity was further supported by variable expression of canonical stromal markers, including FAP, SULF1, VIM, CAV1, and αSMA. Transcription factor network analysis revealed SOX, FOX, and STAT3 family members as key regulators of pro-tumorigenic CAF states. To probe therapeutic vulnerabilities, we performed high-throughput drug sensitivity and resistance testing (DSRT) across 396 oncology compounds. CAFs exhibited broad sensitivity to multikinase inhibitors, with dasatinib, midostaurin, and FGFR inhibitors (AZD4547, erdafitinib) emerging as top stromal-directed candidates. These findings underscore the plasticity of prostate CAFs and reveal actionable vulnerabilities, supporting the development of targeted stromal therapies to disrupt tumor-stroma interactions in PCa.


  • Open Access

    The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

    by Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Tatiana Kudling, Elise Jirovec, Lyna Haybout, Mirte van der Heijden, Sanae Zahraoui, et al.

    Immune checkpoint inhibitors have demonstrated modest efficacy as a monotherapy in ovarian cancer. Originally developed to improve efficacy of T-cell therapies such as immune checkpoint inhibitors and adoptive cell transfer, TILT-123 (Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a serotype chimeric oncolytic adenovirus encoding tumor necrosis factor alpha and interleukin-2. Here we report results from phase 1a of PROTA, a single-arm, multicentre dose escalation trial with TILT-123 and pembrolizumab in female patients with platinum resistant or refractory ovarian cancer (NCT05271318). The primary endpoint was safety. Secondary endpoints included efficacy, tolerability, virus persistence and anti-viral immunity. Patients (n = 15) received intravenous and intraperitoneal and/or intratumoral injections of TILT-123 as well as intravenous pembrolizumab. Treatment was well tolerated, and no dose-limiting toxicities were observed. The most frequent adverse events were fever (40%), fatigue (40%) and nausea (40%). Disease control was achieved in 64% of evaluable patients (9/14). Median progression-free survival and overall survival were 98 and 190 days respectively. Clinical responses were associated with higher serum anti-adenovirus neutralizing antibody titer at baseline and post-treatment. The phase 1b investigating TILT-123, pembrolizumab and PEGylated liposomal doxorubicin in a similar patient population is underway.


  • Open Access

    Fibroblast Activation Protein Defines an Aggressive, Immunosuppressive EMT-associated Tumor Subtype in Highly Inflamed Localized Clear Cell Renal Cell Carcinoma

    by Teijo Pellinen, Lassi Luomala, Kalle E Mattila, Annabrita Hemmes, Katja Välimäki, Oscar Brück, Lassi Paavolainen, Elisa Kankkunen, Harry Nisén, Petrus Järvinen, et al.

    Clear cell renal cell carcinoma (ccRCC) is among the most immune-infiltrated cancers, where high inflammation correlates with poor clinical outcomes. While epithelial-to-mesenchymal transition (EMT), immunosuppression, and cancer-associated fibroblasts (CAFs) have been linked with poor prognosis in metastatic ccRCC, their relevance and interplay in localized disease remain uncertain. To address this gap, we performed single-cell spatial profiling of highly inflamed localized tumors to characterize interactions between EMT-associated cancer cells and immune subsets, aiming to identify tumor microenvironment cell subsets and states responsible for the poor prognosis in highly inflamed ccRCC. Multiplexed immunofluorescence imaging with a 33-marker panel was applied to 1,728 tissue cores collected from tumor centers, invasive borders, and adjacent benign tissue from 435 localized ccRCC patients. Independent discovery (n=196) and validation (n=239) cohorts were used to confirm the significance of identified prognostic markers. Hierarchical clustering revealed TME subsets enriched for CD45⁺ immune cells, CD31⁺ endothelial cells, or fibroblasts. High CD45⁺ cell density significantly correlated with poor recurrence-free survival across tumor regions, including tumor center, invasive border, and adjacent benign tissue. Within tumors exhibiting high CD45⁺ infiltration, EMT-associated cancer cells strongly expressed fibroblast activation protein (FAP) at invasive borders, independently predicting worse prognosis and increased risk of liver metastasis. Furthermore, CD45 high tumors with elevated FAP expression featured immunosuppressive FAP⁺ CAFs, M2-like macrophages, exhausted T cells, and regulatory T cells. Tumor-cell-specific FAP expression was validated as an independent prognostic biomarker in both early-stage localized ccRCC (pT1-2) and patients subsequently developing metastases who received sunitinib, highlighting its potential for improved patient stratification. Significance: FAP expression identifies an aggressive, immunosuppressive EMT-associated subtype of localized ccRCC, uncovering critical interactions between cancer cells and the TME and revealing novel biological insights and therapeutic vulnerabilities driving early-stage ccRCC progression. Graphical Tumor-cell FAP Expression Defines an Aggressive, Immunosuppressive EMT Subtype in Highly Inflamed Localized ccRCC: Localized ccRCC tumors were stratified by CD45⁺ immune infiltration, revealing that CD45 high tumors were associated with significantly poorer recurrence-free survival (5-year RFS rate: 39%). Among these, tumor cell-specific expression of fibroblast activation protein (FAP) identified a particularly aggressive subtype marked by epithelial-to-mesenchymal transition (EMT), reduced endothelial content, and an immunosuppressive tumor microenvironment enriched with M2-like macrophages, regulatory T cells, exhausted T cells, and FAP⁺ cancer-associated fibroblasts (CAFs). FAP⁺ tumors had an even lower 5-year RFS rate of 26%, compared to 50% in FAP⁻ CD45 high tumors. Tumor-cell FAP thus provides an additional layer of risk stratification within the CD45 high subgroup and reflects a biologically distinct, immune-evasive tumor state. These findings highlight FAP as both a potential therapeutic target and imaging biomarker in localized ccRCC.


  • Open Access

    Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma

    by Matilda Roos-Mattila, Pauliina Kallio, Tamara J. Luck, Minttu Polso, Romika Kumari, Piia Mikkonen, Katja Välimäki, Minna Malmstedt, Pekka Ellonen, Teijo Pellinen, et al.

    Clear-cell renal cell carcinoma (ccRCC) is the most common origin of pancreatic metastases (PM). Distinct genomic aberrations, favorable prognosis, and clinical observations on high angiogenesis, and succeeding tyrosine kinase inhibitor (TKI) sensitivity have been reported in PM-ccRCC. However, no functional or single-cell studies have been conducted thus far. We recruited five PM-ccRCC patients and investigated the genomic, single-cell transcriptomic, and drug sensitivity profiles of their patient-derived cells (PDCs). The PM depicted both expected and novel genomic alterations. Further, the transcriptomics differed from both primary and metastatic ccRCC, with upregulations of the PI3K/mTOR and – supporting the clinical observations – angiogenesis pathways. Data integration at pathway level showed that transcriptomics explained drug sensitivities the best. Accordingly, PM-ccRCC PDCs shared sensitivity to many PI3K/mTOR inhibitors. Altogether, we show distinct genomic and transcriptomic signatures in PM-ccRCC, highlight the superiority of transcriptomics in interpreting drug sensitivities, and encourage the use of TKIs and PI3K/mTOR inhibitors in PM-ccRCC.


  • Open Access

    Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell Carcinoma

    by Matilda Juusola, Pauliina Kallio, Tamara Luck, Minttu Polso, Romika Kumari, Piia Mikkonen, Katja Välimäki, Minna Malmstedt, Pekka Ellonen, Teijo Pellinen, et al.

    Pancreatic metastases (PM) of clear cell renal cell carcinoma (ccRCC) are rare, and little is known about them at patient level. The aim of this study was to define the patient-specific characteristics of PM-ccRCC and matching patient-derived cell (PDC) cultures. We describe the genomic and single-cell transcriptomic profiles of five patients with PM-ccRCC as well as the functional drug sensitivities of their PDCs­­. First, the patients’ tumors depicted both common and novel somatic mutations and copy number alterations, which were maintained in their PDCs. Second, we show that PM-ccRCC transcriptomes differ from previously reported signatures for bone metastasis and primary ccRCC. Finally, we find both shared (e.g., PIK3, mTOR inhibitors) and patient-specific (e.g., EGFR, MEK1/2 inhibitors) drug sensitivities. We use integrated multi-omics to illuminate pathway-level deregulations explaining drug sensitivities, and to propose patient-specific druggable pathways. Altogether, our findings suggest enriched molecular profiles in PM-ccRCC and target pathways for PM-ccRCC treatment.